New US Compassionate Use Tool Would Need Support Of Drug Makers
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration and not-for-profit organization, the Reagan-Udall Foundation, are exploring a proposed tool that could make it easier for physicians and patients seeking access to unapproved drugs by providing a central repository of information about biopharma manufacturers' policies and points of contact1,2.
You may also be interested in...
NIH Funding Component of 21st Century Cures May Get White House Boost
Vice President’s Cancer Moonshot project could provide final thrust for '21st Century Cures' bill in the lame duck Congressional session after election.
'Right To Try' Or 'Right To Ask'? Hearing Spotlights Adverse Events As Key Barrier To Expanded Access
FDA and the pharmaceutical industry appear to have a shared interest in finding ways to dramatically increase expanded access programs to avoid a potentially difficult fight over 'Right to Try' legislation at the federal level in 2017. A September 22 hearing on a pending Senate bill illustrates why.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.